Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.46 |
| ▸ | AURKA | O14965 | 1/20 | 0.45 |
| ▸ | PIM1 | P11309 | 1/20 | 0.45 |
| ▸ | CDK2 | P24941 | 1/20 | 0.45 |
| ▸ | GSK3B | P49841 | 1/20 | 0.45 |
| ▸ | HSPA9 | P38646 | 2/20 | 0.45 |
| ▸ | HSPA5 | P11021 | 1/20 | 0.45 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.44 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL288965 | 1.00 | FDPS (0.53) | FDPSLMNATSHRHSD17B10HTT | |
| SCHEMBL43587 | 1.00 | FDPS (0.53) | FDPSLMNATSHRHSD17B10HTT | |
| SCHEMBL14940427 | 0.81 | CTSC (0.49) | LMNATSHRHSD17B10RAB9AHSPA9 | |
| SCHEMBL577833 | 0.77 | — | — | |
| SCHEMBL12966147 | 0.76 | HSPA9 (0.52) | FDPSLMNATSHRHTTNPC1 | |
| SCHEMBL8701148 | 0.76 | FDPS (0.50) | FDPSLMNATSHRHSD17B10HTT | |
| SCHEMBL8701152 | 0.76 | FDPS (0.50) | FDPSLMNATSHRHSD17B10HTT | |
| SCHEMBL4455601 | 0.76 | FDPS (0.46) | FDPSLMNATSHRHTTNPC1 | |
| SCHEMBL4469605 | 0.76 | FDPS (0.46) | FDPSLMNATSHRHTTNPC1 | |
| SCHEMBL4455593 | 0.76 | FDPS (0.46) | FDPSLMNATSHRHTTNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1475 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119015394-A | Sulfur-containing compound preparation, and preparation method and application thereof | 上海优斐斯生物科技有限公司 | 2024-11-26 | — | — | CN | claimed |
| EP-3912641-B1 | HYDROPHILIC DRUG-LINKER COMPOUNDS | SEAGEN INC (US) | 2024-11-06 | — | — | EP | claimed |
| US-20240174715-A1 | PEPTIDE LIBRARIES WITH NON-CANONICAL AMINO ACIDS | INDI MOLECULAR, INC. | 2024-05-30 | — | — | US | claimed |
| US-11919972-B2 | Peptide libraries with non-canonical amino acids | REGENERON PHARMACEUTICALS, INC. (US) | 2024-03-05 | — | — | US | claimed |
| US-20230355708-A1 | COMPOSITIONS FOR INHIBITING VIRAL ENTRY AND METHODS USING SAME | UNIV DREXEL (US) | 2023-11-09 | — | — | US | claimed |
| US-20230132738-A1 | HYDROPHILIC ANTIBODY-DRUG CONJUGATES | SEAGEN INC (US) | 2023-05-04 | — | — | US | claimed |
| US-11510959-B2 | Hydrophilic antibody-drug conjugates | SEAGEN INC. (US) | 2022-11-29 | — | — | US | claimed |
| WO-2022072469-A1 | COMPOSITIONS FOR INHIBITING VIRAL ENTRY AND METHODS USING SAME | DREXEL UNIVERSITY (US) | 2022-04-07 | — | — | WO | claimed |
| EP-3970801-A1 | RAS INHIBITORY PEPTIDE | Ichimaru Pharcos Co., Ltd. (JP) | 2022-03-23 | — | — | EP | claimed |
| CN-113727991-A | Ras inhibitory peptide | 一丸自然美健有限公司 | 2021-11-30 | — | — | CN | claimed |
| US-20070021346-A1 | N-terminally modified GLP-1 receptor modulators | BRISTOL-MYERS SQUIBB COMPANY | 2007-01-25 | — | — | US | claimed |
| US-7160705-B2 | Arginine repressor deficient strain of coryneform bacterium and method for producing L-arginine | AJINOMOTO CO., INC. (JP) | 2007-01-09 | — | — | US | claimed |
| WO-2006127948-A2 | N-TERMINALLY MODIFIED GLP-1 RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-11-30 | — | — | WO | claimed |
| EP-1194531-A2 | CYCLIC PEPTIDOMIMETIC UROKINASE RECEPTOR ANTAGONISTS | Wilex AG (DE) | 2002-04-10 | — | — | EP | claimed |
| US-6232305-B1 | ANTICANCER AGENTS; BONE DISORDERS; ANTIARTHRITIC AGENTS; RESPIRATORY SYSTEM DISORDERS | NAEJA PHARMACEUTICAL INC. (CA) | 2001-05-15 | — | — | US | claimed |
| WO-2001005811-A2 | CYCLIC PEPTIDOMIMETIC UROKINASE RECEPTOR ANTAGONISTS | WILEX AG (DE) | 2001-01-25 | — | — | WO | claimed |
| WO-1997046553-A1 | THROMBIN INHIBITORS | NOVARTIS AG (CH) | 1997-12-11 | — | — | WO | claimed |
| US-4393135-A | GENETICALLY ENGINEERED ESCHERICHIA | AJINOMOTO COMPANY INCORPORATED (JP) | 1983-07-12 | — | — | US | claimed |
| US-4388405-A | ESCHERICHIA INCORPORATED WITH HYBRID PLASMID | AJINOMOTO COMPANY INCORPORATED (JP) | 1983-06-14 | — | — | US | claimed |
| EP-0030391-A2 | Method for producing L-glutamic acid by fermentation and a method for producing a new microorganism | AJINOMOTO CO., INC. (JP) | 1981-06-17 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021346-A1 | N-terminally modified GLP-1 receptor modulators | GLP1R, GIPR, IAPP | FDPS 4020/4885LMNA 2525/4885TSHR 70/4885 |
| US-11510959-B2 | Hydrophilic antibody-drug conjugates | CD44, FCGR1A, FCGR2A | FDPS 4028/4885LMNA 3561/4885TSHR 800/4885 |
| US-20240174715-A1 | PEPTIDE LIBRARIES WITH NON-CANONICAL AMINO ACIDS | ARGLU1, NGLY1, VIP | FDPS 3323/4885LMNA 3601/4885TSHR 1064/4885 |
| US-20230355708-A1 | COMPOSITIONS FOR INHIBITING VIRAL ENTRY AND METHODS USING SAME | GALNT1, GALNT2, LGALS1 | FDPS 1389/4885LMNA 233/4885TSHR 4858/4885 |
| US-20230132738-A1 | HYDROPHILIC ANTIBODY-DRUG CONJUGATES | CD44, FCGR1A, FCGR2A | FDPS 4028/4885LMNA 3561/4885TSHR 800/4885 |
| US-11919972-B2 | Peptide libraries with non-canonical amino acids | ARGLU1, NGLY1, VIP | FDPS 3323/4885LMNA 3601/4885TSHR 1064/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.